Biogen Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc.

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.

Vir Biotechnology (VIR) appointed Johanna Friedl-Naderer as executive vice president and chief business officer, Global, effective March 2, 2022.Prior to joining Vir, Friedl-Naderer

Biogen (BIIB) announced it entered into a commercialization and license agreement with Swedish pharmaceutical company Xbrane Biopharma AB for Xcimzane, a proposed biosimilar to…

Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savings Biosimilars have the potential to broaden patient access to effecti

Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savings Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savings

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some bi

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big pharma earnings. The sector came back up in the final session for a firm finish. Merck & Co., Inc. (NASDAQ: MRK ) issued mixed 2022 guidance and Swiss pharma giant Roche Holding AG (OTC: RHHBY ) warned of slowing growth in 2022. Biogen, Inc. (NASDAQ: BIIB ) shares moved to the downside as they reacted to weak guidance and not-so-promising commentary about sales of the company''s Alzheimer''s drug Aduhelm. On the regulatory front, the Food and Drug Administration approved Viatris Inc.''s (NASDAQ: VTRS ) generic version of AbbVie, Inc.''s (NYSE: ABBV ) dry eye disease drug Restasis. Sanofi (NASDAQ: SNY ) received the nod for its medication Enjaymo, targeting a rare blood disorder known as cold agglutinin disease. LogicBio Therapeutics, Inc. (NASDAQ: LOGC ) shares shed over 50% during the week after the FDA imposed a clinical hold on a Phase 1/2 study of its AAV-delivered genomic editing therapy LB-001 to treat a rate metabolic disorder in children.

The U.S. Federal Trade Commission and the U.S. Securities and Exchange Commission have asked Biogen Inc to provide information on the approval and marketing of its new Alzheimer''s disease treatment, Aduhelm, the drugmaker disclosed in a filing.

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB ) and its Alzheimer''s med, Aduhelm (aducanumab). According to the Company''s annual filing , the FTC has made a civil investigative demand in pursuit of documents related to … Full story available on Benzinga.com

Biogen (BIIB) shares continue to trade lower after the company projected an underwhelming 2022 guidance Thursday

Upgrades CBRE upgraded the previous rating for Penn National Gaming Inc (NASDAQ:PENN) from Hold to Buy. For the fourth quarter, Penn National Gaming had an EPS of $0.26, compared to year-ago quarter

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc BIIB and its Alzheimer's med, Aduhelm (aducanumab). Get

Friday''s top analyst upgrades and downgrades included Agnico-Eagle Mines, Biogen, Exelon, Meta Platforms, New York Times, PulteGroup, Snap and Vertex Pharmaceutical.

Shares of Biogen Inc. tumbled 2.2% in premarket trading on Friday after the company disclosed in a securities filing that it received a civil investigative demand from the Federal Trade Commission and an inquiry from the Securities and Exchange Commission in relation to Aduhelm, its new Alzheimer''s disease drug. The SEC inquiry is requesting information about the sites that administer the drug, the regulatory approval, and Biogen''s marketing for the therapy, the company said. The Food and Drug Administration approved the controversial drug in June of last year; it''s been criticized for several reasons, including how it was priced and the clinical data used to inform the approval process. The drug generated a total of $3 million in revenue in 2021. Biogen''s stock is down 17.6% for the past year. The S&P 500 is up 17.9%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.